SP
SPRB.US Spruce Biosciences, Inc. Common Stock
- Market cap
- USD 116M
- P/E
- -
- P/B
- 1.85x
- ROE
- -105.6%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is SPRB.US undervalued?
Graham numberThe Graham number of Spruce Biosciences, Inc. Common Stock cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Spruce Biosciences, Inc. Common Stock fundamental analysis
No fundamental analysis for Spruce Biosciences, Inc. Common Stock yet.
Spruce Biosciences, Inc. Common Stock stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Spruce Biosciences, Inc. Common Stock
Spruce Biosciences, Inc. is a biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders. The company develops TA-ERT, a fusion protein comprised of recombinant human alpha-N-acetylglucosaminidase, which is an enzyme replacement therapy for patients with Sanfilippo Syndrome Type B. It also develops Tildacerfont for treating a highly debilitating mental disorder characterized by depressed mood with cognitive-affective and so…
Full company profileSpruce Biosciences, Inc. Common Stock financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Spruce Biosciences, Inc. Common Stock annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 1.96M | 10.1M | 4.91M | 0.00 | 0.00 |
| Gross Profit | -1.00K | -12.0K | -102K | -381K | -429K | 10.1M | 4.91M | -21.0K | - |
| Operating Income | -9.97M | -13.1M | -29.4M | -42.1M | -47.3M | -52.0M | -56.2M | -36.5M | -70.0M |
| EBITDA | -9.97M | -13.0M | -29.4M | -41.9M | -45.7M | -47.4M | -52.7M | -38.9M | -63.9M |
| Net Income | -9.86M | -13.2M | -29.5M | -42.3M | -46.2M | -47.9M | -53.0M | -39.0M | -70.0M |
| EPS | -496 | -23 | -49 | -70 | -75 | -96 | -99 | -51 | -25 |
| Balance Sheet | |||||||||
| Total Assets | 4.78M | 4.69M | 163M | 126M | 85.6M | 104M | 45.2M | 53.0M | 91.9M |
| Total Liabilities | 22.6M | 35.3M | 13.5M | 15.1M | 17.2M | 27.4M | 16.4M | 10.5M | 25.7M |
| Shareholders' Equity | -17.8M | -30.6M | 149M | 111M | 68.5M | 76.5M | 28.8M | 42.5M | 66.3M |
| Cash & Short-term Investments | 4.11M | 3.92M | 157M | 89.0M | 79.1M | 96.3M | 38.8M | 48.9M | 87.7M |
| Total Debt | - | 4.45M | 6.38M | 6.53M | 6.32M | 4.61M | 2.77M | 736K | 8.32M |
| Cash Flow | |||||||||
| Operating Cash Flow | -8.57M | -12.6M | -27.5M | -35.9M | -41.7M | -33.3M | -56.0M | -33.3M | -59.5M |
| Capital Expenditure | 4.00K | 4.00K | 74.0K | 93.0K | 8.00K | 7.00K | 0.00 | 0.00 | 193K |
| Free Cash Flow | -8.57M | -12.6M | -27.6M | -36.0M | -41.7M | -33.3M | -56.0M | -33.3M | -59.7M |
| Ratios | |||||||||
| ROE | - | - | -19.8% | -38.0% | -67.4% | -62.6% | -184.0% | -91.7% | -105.6% |
| ROA | -206.5% | -282.1% | -18.1% | -33.4% | -53.9% | -46.1% | -117.3% | -73.5% | -76.1% |
| Net Profit Margin | - | - | - | - | -2,351.3% | -475.0% | -1,079.9% | - | - |
| Debt to Equity | - | - | 0.04x | 0.06x | 0.09x | 0.06x | 0.10x | 0.02x | 0.13x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Spruce Biosciences, Inc. Common Stock dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | USD 169K | 0.34 | - |
| 2022 | - | - | - |
| 2021 | USD 423K | 0.70 | - |
| 2020 | - | - | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:75 on Aug 7, 2025.
Who owns Spruce Biosciences, Inc. Common Stock
- Insiders 3.37%
- Institutions 74.30%
- Public & others 22.32%
- Shares outstanding 2.87M
- Free float 2.01M
Top funds holding SPRB.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 84.9K | 2.96% | 0.00% | Sep 2026 |
| Biotech Growth Ord | 67.8K | 2.36% | 0.00% | Jul 2026 |
| iShares Russell 2000 ETF | 67.2K | 2.34% | 0.00% | Oct 2026 |
| Fidelity Small Cap Index | 29.7K | 1.03% | 0.00% | Aug 2026 |
| iShares Russell 2000 Value ETF | 17.7K | 0.62% | 0.00% | Oct 2026 |
| Vanguard Russell 2000 ETF | 14.4K | 0.50% | -7.85% | Sep 2026 |
| Fidelity Extended Market Index | 13.1K | 0.46% | -0.37% | Sep 2026 |
| iShares Micro-Cap ETF | 7.48K | 0.26% | 0.00% | Oct 2026 |
| iShares Russell 2000 Growth ETF | 6.60K | 0.23% | -0.36% | Oct 2026 |
| Fidelity Total Market Index | 6.37K | 0.22% | -0.05% | Sep 2026 |
| Schwab Small Cap Index | 6.07K | 0.21% | -10.67% | Sep 2026 |
| Bridge Builder Small Cap Fund | 5.39K | 0.19% | 0.00% | Oct 2026 |
| iShares Russell 2000 Small-Cap Idx Instl | 5.08K | 0.18% | 0.00% | Sep 2026 |
| Fidelity Series Total Market Index | 4.26K | 0.15% | 0.00% | Sep 2026 |
| Dimensional US Small Cap ETF | 3.75K | 0.13% | 0.00% | Oct 2026 |
| Stt Strt SPDR® Russell2000 US SmCapETF | 3.00K | 0.10% | -5.78% | Oct 2026 |
| EQ/2000 Managed Volatility IB | 2.93K | 0.10% | 0.00% | Sep 2026 |
| Fidelity Small Cap Value Index | 2.93K | 0.10% | +3.31% | Aug 2026 |
Top institutions holding SPRB.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| AIGH Capital Management, LLC | 250K | 8.70% | 0.00% | Jun 2026 |
| Orbimed Advisors LLC | 200K | 6.96% | 0.00% | Jun 2026 |
| BlackRock Inc | 188K | 6.54% | +1,008.96% | Jun 2026 |
| Millennium Management LLC | 161K | 5.60% | +43.88% | Jun 2026 |
| Ikarian Capital, LLC | 121K | 4.22% | 0.00% | Jun 2026 |
| Vanguard Capital Management, LLC | 119K | 4.15% | +550.77% | Jun 2026 |
| Alyeska Investment Group, L.P. | 81.7K | 2.84% | +58.06% | Jun 2026 |
| Geode Capital Management, LLC | 70.5K | 2.45% | +447.35% | Jun 2026 |
| ADAR1 Capital Management LLC | 67.7K | 2.36% | +15.56% | Jun 2026 |
| Cable Car Capital LLC | 60.0K | 2.09% | 0.00% | Jun 2026 |
| Citadel Advisors Llc | 51.9K | 1.81% | -25.85% | Jun 2026 |
| State Street Corp | 50.5K | 1.76% | +834.26% | Jun 2026 |
| BOOTHBAY FUND MANAGEMENT, LLC | 42.1K | 1.46% | 0.00% | Jun 2026 |
| StemPoint Capital LP | 41.4K | 1.44% | +225.38% | Jun 2026 |
| Eversept Partners, LP | 40.0K | 1.39% | 0.00% | Jun 2026 |
| The Carlyle Group Inc | 38.6K | 1.34% | 0.00% | Jun 2026 |
| The Goldman Sachs Group Inc | 32.3K | 1.13% | +487.50% | Jun 2026 |
| Affinity Asset Advisors, LLC | 30.0K | 1.04% | 0.00% | Jun 2026 |
| Diadema Partners LP | 30.0K | 1.04% | +200.00% | Jun 2026 |
| Stonepine Capital Management Llc | 28.8K | 1.00% | 0.00% | Jun 2026 |
Spruce Biosciences, Inc. Common Stock company profile
- Company name
- Spruce Biosciences, Inc. Common Stock
- Ticker
- SPRB.US
- Exchange
- USA Stocks
- Listed since
- Oct 9, 2020
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 25
- Fiscal year end
- December
- Address
- 611 Gateway Boulevard, South San Francisco, CA, United States, 94080
- Phone
- 415 343 5986
- Website
- sprucebio.com
About Spruce Biosciences, Inc. Common Stock
Spruce Biosciences, Inc. is a biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders. The company develops TA-ERT, a fusion protein comprised of recombinant human alpha-N-acetylglucosaminidase, which is an enzyme replacement therapy for patients with Sanfilippo Syndrome Type B. It also develops Tildacerfont for treating a highly debilitating mental disorder characterized by depressed mood with cognitive-affective and somatic changes, including anhedonia, weight alterations, and altered sleeping patterns. In addition, the company develops SPR202 for the treatment of Congenital Adrenal Hyperplasia (CAH), a chronic and potentially life-threatening rare disease with no cure. The company has a license agreement with Eli Lilly and Company to research, develop, and commercialize various pharmaceutical compounds. It also has a collaboration and license agreement with Kaken Pharmaceutical Co. Ltd. to develop, manufacture, and commercialize Tildacerfont for the treatment of CAH in Japan. Spruce Biosciences, Inc. was incorporated in 2014 and is headquartered in South San Francisco, California.
Spruce Biosciences, Inc. Common Stock management
9- Mr. Michael G. GreyExecutive Chairman · born 1953
- Dr. Javier Szwarcberg M.D., M.P.H.CEO & Director · born 1970
- Mr. Samir M. Gharib CPA, M.B.A.President & CFO · born 1982
- Mr. Bruno Gagnon BPHARM, M.Sc.Senior Vice President of Clinical Development Operations · born 1969
- Dr. Daven Mody M.B.A., Pharm.D.Senior Vice President of Regulatory & Quality
- Mr. Corwin Dale Hooks M.B.A.Chief Commercial Officer · born 1967
- Dr. Adrian Quartel FFPM, M.D.Chief Medical Officer · born 1961
- Ms. Saba Sile M.D.Senior Vice President of Clinical Development
- Ms. Tina Gullotta CPAVice President of Finance and Corporate Controller · born 1974